What is Melphalan-prednisone-lenalidomide (MPL)?

Category: Prescription Drugs


See also: Lenalidomide Melphalan

Melphalan-prednisone-lenalidomide, also known as MPL, is a regimen that may be used for the treatment of multiple myeloma in patients that are not candidates for a stem cell transplant. It contains the anticancer agents lenalidomide and melphalan along with prednisone, a corticosteroid.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple myeloma 32 1
Butterfly (malar) rash 1 0
Pain 1 0
Pain in lower back 1 0
Rheumatoid arthritis 1 0
Shortness of breath (dyspnea) 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 1
Moderate 0
Mild 0
None 0

Commonly reported side effects and conditions associated with Melphalan-prednisone-lenalidomide (MPL)

Side effect Patients Percentage
Peripheral neuropathy 1

Why patients stopped taking Melphalan-prednisone-lenalidomide (MPL)

Multiple reasons could be selected

Reason Patients Percentage
Doctor's advice 1
See all 2 patients who've stopped taking Melphalan-prednisone-lenalidomide (MPL)


Stopped taking Melphalan-prednisone-lenalidomide (MPL)

Duration Patients Percentage
Less than 1 month 1
2 - 5 years 1
Adherence Evaluations Percentage
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for Melphalan-prednisone-lenalidomide (MPL).